Anika Therapeutics (ANIK) Operating Expenses (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Operating Expenses data on file, last reported at $24.5 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 29.11% year-over-year to $24.5 million in Q1 2026; TTM through Mar 2026 was $80.4 million, a 2.28% increase from a year earlier, with the FY2025 full-year figure at $74.9 million, down 7.7% from the prior year.
• Operating Expenses for Q1 2026 stood at $24.5 million, up from $18.5 million in the prior quarter.
• Over the last five years, Operating Expenses for ANIK reached as high as $35.4 million in Q1 2023 and fell as low as -$18.9 million in Q4 2023.
• Historically, Operating Expenses has averaged $19.5 million across 5 years, with a median of $21.5 million in 2024.
• Across the five-year window, Operating Expenses slumped 146.33% in 2022 and surged 194.2% in 2024, its largest moves.
• Year by year, Operating Expenses stood at -$12.6 million in 2022, then tumbled by 49.9% to -$18.9 million in 2023, then surged by 194.2% to $17.8 million in 2024, then advanced by 3.94% to $18.5 million in 2025, then jumped by 32.12% to $24.5 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $24.5 million in Q1 2026, $18.5 million in Q4 2025, and $18.8 million in Q3 2025.